MAO-B Polymorphism Associated with Progression in a Chinese Parkinson’s Disease Cohort but Not in the PPMI Cohort

Table 1

Cohort demographics at baseline.

Item	TW (N = 50)	PPMI (N = 413)
	Median (IQR)/n (%)	Median (IQR)/n (%)
Age of onset, yrs	58 (9)	60.45 (13.8)
Age, yrs	63 (8.75)	62.37 (13.99)
Duration, yrs	4 (4)	4.23 (5.28)
Educ: 0–6	3 (6.38)	2 (0.48)
Educ: 7–9	17 (36.17)	7 (1.69)
Educ: 10–12	13 (27.66)	65 (15.66)
Educ:≥13	14 (29.79)	341 (82.17)
Sex: male	30 (60)	270 (65.06)
Sex: female	20 (40)	145 (34.94)
Hoehn-Yahr staging	1.5 (1)	2 (1)
MDS-UPDRS	27.5 (30)	31 (17)
MDS-UPDRSI	4 (8)	5 (4)
MDS-UPDRSII	7 (7)	5 (5)
MDS-UPDRSIII	14 (16.75)	20 (12)
MDS-UPDRSIV	0 (0)	—
ESS	4.5 (5)	5 (5)
HAMA or STAI	6 (7)	62 (24)
HAMD-17 or GDS	5 (5)	2 (2)
MoCA	25 (5)	27 (3)
RBD-HK or RBD-Q	7 (23)	3 (3.25)
SCOPA-AUT	7.5 (12)	8 (7)

ESS, Epworth sleepiness scale score; GDS, geriatric depression scale; HAMA, Hamilton anxiety rating scale; HAMD-17, Hamilton rating scale for depression; MDS-UPDRS, MDS-unified Parkinson’s disease rating scale; MoCA, Montreal cognitive assessment; PPMI, parkinson’s progression markers initiative; RBD-HK, rapid eye movement sleep behavior disorder Hong Kong; RBD-Q, rapid eye movement sleep behavior disorder questionnaire; SCOPA-AUT, scales for outcomes in parkinson’s disease-autonomic dysfunction; STAI, state-trait anxiety inventory for adults.